Category Archives: Strategy
By Pharm Exec | Published: October 29, 2014
After having already sequenced thousands of cancer genes in projects together, the Yale School of Medicine and Gilead announced they will continue their partnership to find therapeutic candidates for cancer for an additional three years. The original agreement was forged in 2011 and can be renewed for up to 10 years.
By Guest Blogger | Published: October 27, 2014
After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover? This Applied Clinical Trials article discusses some background on Pfizer’s financial history, evaluates its R&D portfolio, and determines whether it is ready for another acquisition attempt. Read more…
By Pharm Exec | Published: October 23, 2014
The recent termination of AbbVie’s deal to acquire Shire has “jolted the industry out of its reverie” by becoming pharma’s first major casualty of new US tax inversion legislation, says research and consulting firm GlobalData.
By Guest Blogger | Published: October 23, 2014
By Jim Miller. Exits from the CMO industry are a more recent development that seems to be picking up momentum. Examples of CMOs leaving the industry in the past year include the contract manufacturing units of Bayer and Boehringer-Ingelheim; Pharmalucence; and SCM Pharma. There have been two principal drivers of these developments: growing demand for […]
By Pharm Exec | Published: October 15, 2014
In this special issue of Pharm Exec Global Digest: Unlocking the true value of Big Data; Data privacy and the health sciences; In-silico modeling and real-word outcomes; and more… Click here to access the issue.